8.6 Enzyme Inhibition Modes & Allosteric Cooperativity
Key Takeaways
Reversible enzyme inhibition modes produce distinct kinetic profiles: competitive inhibitors increase apparent Km with Vmax unchanged (overcome by high [S]); pure noncompetitive inhibitors decrease Vmax with Km unchanged; uncompetitive inhibitors bind exclusively to the ES complex, decreasing both apparent Km and Vmax by identical proportions to yield parallel Lineweaver-Burk lines; mixed inhibitors alter both parameters.
Irreversible inhibitors form a covalent adduct with the enzyme and cannot be displaced by raising substrate concentration, so they lower Vmax in proportion to the fraction of enzyme permanently inactivated; aspirin acetylating cyclooxygenase and organophosphates phosphorylating acetylcholinesterase are the canonical examples.
Allosteric enzymes are multi-subunit proteins whose cooperative substrate binding produces a sigmoidal rather than hyperbolic velocity curve, and they are regulated by effectors that bind outside the active site; covalent activation of secreted zymogens such as chymotrypsinogen provides a separate, irreversible layer of control.
8.6 Enzyme Inhibition Modes & Allosteric Cooperativity
Reversible and Irreversible Enzyme Inhibition
Enzyme inhibitors are chemical agents that suppress catalytic velocity. They are broadly partitioned into reversible and irreversible classes.
1. Competitive Inhibition
- Mechanism: The inhibitor structurally resembles the natural substrate and binds reversibly to the free enzyme active site, competing directly with substrate binding (E + I ⇌ EI).
- Kinetic Effect:
- Vmax is Unchanged: At infinite [S], substrate molecules outcompete the inhibitor for active sites, driving all enzyme into the ES complex.
- Apparent Km Increases (Km,app = α Km, where α = 1 + [I]/Ki): More substrate is required to achieve half-saturation, reflecting reduced apparent affinity.
- Lineweaver-Burk Signature:
- Identical y-intercept (1/Vmax unchanged).
- x-intercept moves closer to the origin (becomes less negative, as -1/Km,app > -1/Km).
- Slope increases (lines intersect on the y-axis).
2. Pure Noncompetitive Inhibition
- Mechanism: The inhibitor binds to an allosteric regulatory site distinct from the active site. In pure noncompetitive inhibition, the inhibitor binds to the free enzyme (E) and the enzyme-substrate complex (ES) with identical affinity (Ki = Ki'). Substrate binding is not blocked, but catalysis cannot proceed (ESI → no product).
- Kinetic Effect:
- Vmax Decreases (Vmax,app = Vmax / α): Removing a fraction of functional enzyme molecules effectively decreases [E]total; cannot be overcome by adding substrate.
- Km is Unchanged: The inhibitor does not alter the affinity of the remaining active sites for substrate.
- Lineweaver-Burk Signature:
- Identical x-intercept (-1/Km unchanged).
- y-intercept shifts upward (1/Vmax,app increases).
- Slope increases (lines intersect on the negative x-axis).
3. Uncompetitive Inhibition
- Mechanism: The inhibitor binds exclusively to the enzyme-substrate (ES) complex at an allosteric pocket created only after substrate induces a conformational change (ES + I ⇌ ESI).
- Kinetic Effect:
- Vmax Decreases (Vmax,app = Vmax / α'): ESI complexes cannot turn over to product.
- Apparent Km Decreases (Km,app = Km / α'): By Le Chatelier's principle, binding of inhibitor to ES depletes free ES, pulling the E + S ⇌ ES equilibrium forward. This appears experimentally as an increased affinity for substrate.
- Constant Ratio: Because both Vmax and Km are reduced by the exact same factor (α'), the slope of the Lineweaver-Burk plot (Km/Vmax) remains completely constant!
- Lineweaver-Burk Signature:
- A family of parallel lines shifted upward and to the left (y-intercept increases, x-intercept becomes more negative).
4. Mixed Inhibition
- Mechanism: The inhibitor binds to an allosteric site on both free E and the ES complex, but with unequal affinities (Ki ≠ Ki').
- If Ki < Ki' (prefers free E): Km increases, Vmax decreases (intersection occurs above the x-axis in Quadrant II).
- If Ki' < Ki (prefers ES complex): Km decreases, Vmax decreases (intersection occurs below the x-axis in Quadrant III).
5. Irreversible Inhibition (Suicide / Mechanism-Based Inhibition)
- Mechanism: Inhibitor binds covalently to active-site catalytic residues or forms an ultra-tight non-covalent complex (Kd < 10^-12 M) that dissociates extremely slowly.
- Kinetic Effect: Permanently destroys active enzyme molecules. Kinetically mimics noncompetitive inhibition (reduces apparent Vmax while leaving Km unchanged), but cannot be reversed by dilution, washing, or dialysis.
- Representative Examples: Aspirin (acetylates Ser530 of cyclooxygenase-1/2); Penicillin (covalently acylates catalytic serine of bacterial transpeptidase); Diisopropyl fluorophosphate / DFP (organophosphate that phosphorylates catalytic serine of acetylcholinesterase).
Summary Table of Reversible Enzyme Inhibition Modes
| Inhibition Type | Binding Site / Target | Apparent Vmax | Apparent Km | Lineweaver-Burk Graphical Intersection |
|---|---|---|---|---|
| Competitive | Active site on free enzyme (E) only | Unchanged | Increases (Km × α) | Intersects on the y-axis (1/Vmax) |
| Pure Noncompetitive | Allosteric site on E and ES equally (Ki = Ki') | Decreases (Vmax / α) | Unchanged | Intersects on the negative x-axis (-1/Km) |
| Uncompetitive | Allosteric site on ES complex only | Decreases (Vmax / α') | Decreases (Km / α') | Parallel lines (no intersection; slope unchanged) |
| Mixed (Ki < Ki') | Allosteric site on E and ES (prefers E) | Decreases (Vmax / α') | Increases | Intersects in Quadrant II (left of y, above x) |
| Mixed (Ki' < Ki) | Allosteric site on E and ES (prefers ES) | Decreases (Vmax / α') | Decreases | Intersects in Quadrant III (left of y, below x) |
Allosteric Enzymes & Sigmoidal Cooperativity
Not all enzymes follow hyperbolic Michaelis-Menten kinetics. Allosteric enzymes display a sigmoidal (S-shaped) curve of initial velocity versus substrate concentration.
- Structure: Allosteric enzymes are multi-subunit oligomers with multiple active sites that exhibit cooperativity.
- Homotropic Regulation: The substrate itself acts as an allosteric activator. Substrate binding at one active site converts adjacent subunits from the low-affinity T (tense) state to the high-affinity R (relaxed) state.
- Heterotropic Regulation: A regulatory molecule distinct from the substrate binds to an independent allosteric site:
- Positive Allosteric Modulator (Activator): Stabilizes the R-state, shifting the sigmoidal curve to the left (lowers K0.5, accelerating velocity at sub-saturating substrate levels).
- Negative Allosteric Modulator (Inhibitor): Stabilizes the T-state, shifting the sigmoidal curve to the right (increases K0.5, requiring higher substrate concentrations to reach velocity thresholds; often seen in feedback inhibition of metabolic pathways, such as CTP inhibiting aspartate transcarbamoylase / ATCase).
An investigator examines the kinetic profile of a novel candidate compound, Drug X, against bacterial dihydrofolate reductase. In the presence of Drug X, double-reciprocal Lineweaver-Burk plots demonstrate a family of parallel lines that never intersect, where increasing inhibitor concentrations shift the lines progressively upward and to the left. What mode of inhibition does Drug X exhibit, and how do its apparent kinetic parameters compare to the uninhibited enzyme?
Drug X is a competitive inhibitor; its apparent Vmax is unchanged while its apparent Km increases because Drug X competes with substrate for the free active site.
Drug X is a pure noncompetitive inhibitor; its apparent Vmax decreases while its apparent Km remains unchanged because Drug X binds with equal affinity to free E and the ES complex.
Drug X is an irreversible suicide inhibitor; its apparent Vmax decreases while its apparent Km increases due to covalent modification of catalytic active-site residues.
Drug X is an uncompetitive inhibitor; both its apparent Vmax and apparent Km decrease by the exact same proportion, resulting in an identical slope (Km/Vmax) and parallel Lineweaver-Burk lines.
In the human digestive cascade, the pancreatic proenzyme chymotrypsinogen is secreted into the duodenum where it is activated to alpha-chymotrypsin through cleavage by trypsin and autolysis. How is chymotrypsin classified under International Enzyme Commission (EC) guidelines, and what biochemical mechanism governs its activation from chymotrypsinogen?
Chymotrypsin is an oxidoreductase (EC 1) that catalyzes hydride transfer; it is activated by the reversible non-covalent binding of an allosteric magnesium cofactor.
Chymotrypsin is a transferase (EC 2) that transfers aminoacyl groups; it is activated through reversible phosphorylation by protein kinase A.
Chymotrypsin is a lyase (EC 4) that cleaves peptide bonds without water; it is activated by positive homotropic cooperativity upon substrate binding.
Chymotrypsin is a hydrolase (EC 3) that cleaves peptide bonds via water addition; it is synthesized as an inactive zymogen to protect the pancreas from autodigestion and is activated irreversibly through specific proteolytic cleavage.
Sections you finish are checked off in the contents.